Articles

At the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, several sessions focused on recent advances in melanoma, including new ways to boost the activity of current therapies, the development of a new class of immunotherapy, and a new form of immunotherapy—an oncolytic vaccine. Read More ›

Protecting the skin from the sun should be considered a year-round necessity because our skin is constantly exposed to the sun’s ultraviolet rays and is thus susceptible to melanoma. Read More ›

Sorafenib has become the first drug in years to prove effective in the treatment of differentiated thyroid cancer (DTC) that has become resistant to radioactive iodine (RAI), according to phase 3 study results reported at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting. Read More ›

Read More ›

In November 2011, Mission Health, located in Asheville, North Carolina, opened the Mission SECU Cancer Center to provide comprehensive cancer care that includes state-of-the-art technology and comfortable, effective treatment delivery. Read More ›

The 2013 American Society of Clinical Oncology (ASCO) Annual Meeting brought approximately 30,000 cancer specialists to Chicago, Illinois, from May 31 to June 4, 2013. Read More ›

Updates to the Clinical Practice Guidelines of the National Comprehensive Cancer Network (NCCN) were presented at the NCCN’s 2013 Annual Conference. Read More ›

For years, the cancer research community has pushed for the use of surrogate end points in clinical trials as a means of hastening the drug approval process. Read More ›

MMA talks about how much she appreciates her oncology nurses, but notes that there are some things they have not done. Read More ›

Noncervical human papilloma virus (HPV)–associated oral and anal cancers are on the rise in the United States in men and women. Read More ›